On the public citation graph
Acetyl‐coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double‐blind, crossover study
0 signed · 142 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/hep.23719openalex-snapshot
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis
inferredcites →https://doi.org/10.1002/jcb.21077openalex-snapshot
Acetyl‐coenzyme A carboxylases: Versatile targets for drug discovery
inferredcites →https://doi.org/10.1007/s00125-009-1405-9openalex-snapshot
Synthesis of specific fatty acids contributes to VLDL-triacylglycerol composition in humans with and without type 2 diabetes
inferredcites →https://doi.org/10.1016/j.bcp.2010.12.014openalex-snapshot
Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation
inferredcites →https://doi.org/10.1016/s0168-8278(16)00866-7openalex-snapshot
NDI-010976, A Potent, Liver-Directed, Oral Inhibitor of Acetyl Coa Carboxylase for Non-Alcoholic Steatohepatitis: A Phase 1 Single Ascending Dose Study in Healthy Volunteers
inferredcites →https://doi.org/10.1021/jm5016022openalex-snapshot
Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes
inferredcites →https://doi.org/10.1038/nm.3372openalex-snapshot
Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin
inferredcites →https://doi.org/10.1038/sj.ejcn.1600744openalex-snapshot
De novo lipogenesis in humans: metabolic and regulatory aspects
inferredcites →https://doi.org/10.1042/bj1260295openalex-snapshot
The immediate effects of insulin and fructose on the metabolism of the perfused liver. Changes in lipoprotein secretion, fatty acid oxidation and esterification, lipogenesis and carbohydrate metabolism
inferredcites →https://doi.org/10.1053/j.gastro.2007.11.038openalex-snapshot
Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1053/j.gastro.2013.11.049openalex-snapshot
Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1056/nejmoa0907929openalex-snapshot
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1073/pnas.0630588100openalex-snapshot
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
inferredcites →https://doi.org/10.1073/pnas.1520686113openalex-snapshot
Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats
inferredcites →https://doi.org/10.1074/jbc.m304481200openalex-snapshot
Isozyme-nonselective N-Substituted Bipiperidylcarboxamide Acetyl-CoA Carboxylase Inhibitors Reduce Tissue Malonyl-CoA Concentrations, Inhibit Fatty Acid Synthesis, and Increase Fatty Acid Oxidation in Cultured Cells and in Experimental Animals
inferredcites →https://doi.org/10.1080/00498250600861751openalex-snapshot
Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition
inferredcites →https://doi.org/10.1124/jpet.112.200691openalex-snapshot
Cynomolgus Monkey as a Potential Model to Assess Drug Interactions Involving Hepatic Organic Anion Transporting Polypeptides: In Vitro, In Vivo, and In Vitro-to-In Vivo Extrapolation
inferredcites →https://doi.org/10.1124/mol.108.048991openalex-snapshot
Role of the Murine Organic Anion-Transporting Polypeptide 1b2 (Oatp1b2) in Drug Disposition and Hepatotoxicity
inferredcites →https://doi.org/10.1136/flgastro-2013-100403openalex-snapshot
Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
inferredcites →https://doi.org/10.1146/annurev.nutr.17.1.77openalex-snapshot
REGULATION OF MAMMALIAN ACETYL-COENZYME A CARBOXYLASE
inferredcites →https://doi.org/10.1152/ajpendo.00644.2005openalex-snapshot
Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells
inferredcites →https://doi.org/10.1152/ajpendo.1992.263.5.e988openalex-snapshot
Mass isotopomer distribution analysis: a technique for measuring biosynthesis and turnover of polymers
inferredcites →https://doi.org/10.1172/jci23621openalex-snapshot
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1194/jlr.m600200-jlr200openalex-snapshot
Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans
inferredcites →https://doi.org/10.1194/jlr.m800165-jlr200openalex-snapshot
A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes
inferredcites →https://doi.org/10.1517/14728222.9.2.267openalex-snapshot
Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition
inferredcites →https://doi.org/10.3945/ajcn.112.038695openalex-snapshot
Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1002/1873-3468.13097openalex-snapshot
Activity and structure of human acetyl‐CoA carboxylase targeted by a specific inhibitor
inferred← citeshttps://doi.org/10.1002/cpdd.782openalex-snapshot
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study
inferred← citeshttps://doi.org/10.1002/cpt.2105openalex-snapshot
Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat
inferred← citeshttps://doi.org/10.1002/elps.201800514openalex-snapshot
Capillary electrophoretic assay of human acetyl‐coenzyme A carboxylase 2
inferred← citeshttps://doi.org/10.1002/hep.30097openalex-snapshot
Acetyl‐CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents
inferred← citeshttps://doi.org/10.1002/hep.31000openalex-snapshot
Fatty Acid Synthase Inhibitor TVB‐2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities
inferred← citeshttps://doi.org/10.1002/hep.31622openalex-snapshot
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
inferred← citeshttps://doi.org/10.1002/jcph.2427openalex-snapshot
Pharmacokinetics and Safety of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment
inferred← citeshttps://doi.org/10.1002/jcph.6114openalex-snapshot
Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non‐Japanese Participants
inferred← citeshttps://doi.org/10.1002/jgh3.12274openalex-snapshot
Sodium‐glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin‐resistant patients without type 2 diabetes
inferred← citeshttps://doi.org/10.1007/978-3-030-11748-1_9openalex-snapshot
Isotopic Tracers for the Measurement of Metabolic Flux Rates
inferred← citeshttps://doi.org/10.1007/978-981-97-9519-2_4openalex-snapshot
Liver Steatosis: From Lipotoxicity to Cellular Damage
inferred← citeshttps://doi.org/10.1007/s00535-021-01796-xopenalex-snapshot
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
inferred← citeshttps://doi.org/10.1007/s12551-019-00602-6openalex-snapshot
Structures, functions, and mechanisms of filament forming enzymes: a renaissance of enzyme filamentation
inferred← citeshttps://doi.org/10.1007/s13311-020-00926-2openalex-snapshot
Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis
inferred← citeshttps://doi.org/10.1007/s40262-024-01420-0openalex-snapshot
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug–Drug Interactions for Firsocostat, a Liver-Targeted Inhibitor of Acetyl-CoA Carboxylase
inferred← citeshttps://doi.org/10.1016/j.anifeedsci.2025.116342openalex-snapshot
Interactions between different single protein and feeding level on growth performance, hepatic lipid metabolism and health of largemouth bass (Micropterus salmoides)
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2022.07.010openalex-snapshot
Impact of NAFLD and its pharmacotherapy on lipid profile and CVD
inferred← citeshttps://doi.org/10.1016/j.atherosclerosis.2024.119066openalex-snapshot
De novo lipid synthesis in cardiovascular tissue and disease
inferred← citeshttps://doi.org/10.1016/j.biopha.2018.11.088openalex-snapshot
A novel resveratrol-curcumin hybrid, a19, attenuates high fat diet-induced nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.celrep.2023.112319openalex-snapshot
Malonylation of Acetyl-CoA carboxylase 1 promotes hepatic steatosis and is attenuated by ketogenic diet in NAFLD
inferred← citeshttps://doi.org/10.1016/j.cgh.2018.04.042openalex-snapshot
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.drudis.2017.06.007openalex-snapshot
Mouse models of nonalcoholic steatohepatitis in preclinical drug development
inferred← citeshttps://doi.org/10.1016/j.jhep.2023.10.042openalex-snapshot
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
inferred← citeshttps://doi.org/10.1016/j.jhepr.2022.100479openalex-snapshot
Lipid alterations in chronic liver disease and liver cancer
inferred← citeshttps://doi.org/10.1016/j.molmed.2017.09.001openalex-snapshot
Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders
inferred← citeshttps://doi.org/10.1016/j.molmed.2021.11.002openalex-snapshot
Targeting ACC for NASH resolution
inferred← citeshttps://doi.org/10.1016/j.nut.2024.112617openalex-snapshot
Revisiting the concepts of de novo lipogenesis to understand the conversion of carbohydrates into fats: Stop overvaluing and extrapolating the renowned phrase “fat burns in the flame of carbohydrate”
inferred← citeshttps://doi.org/10.1016/j.tjnut.2023.09.018openalex-snapshot
Isotope Labeling and Biochemical Assessment of Liver-Triacylglycerol in Patients with Different Levels of Histologically-Graded Liver Disease
inferred← citeshttps://doi.org/10.1016/j.xcrm.2021.100474openalex-snapshot
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study
inferred← citeshttps://doi.org/10.1016/j.yexcr.2021.112787openalex-snapshot
miR-23b Ameliorates nonalcoholic steatohepatitis by targeting Acyl-CoA thioesterases 4
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.0c00640openalex-snapshot
Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.8b00294openalex-snapshot
Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction
inferred← citeshttps://doi.org/10.1021/acs.joc.3c01374openalex-snapshot
Convergent Syntheses of Isomeric Imidazolospiroketones as Templates for Acetyl-CoA Carboxylase (ACC) Inhibitors
inferred← citeshttps://doi.org/10.1038/s41392-022-01119-3openalex-snapshot
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
inferred← citeshttps://doi.org/10.1038/s41419-020-03075-8openalex-snapshot
USP7 mediates pathological hepatic de novo lipogenesis through promoting stabilization and transcription of ZNF638
inferred← citeshttps://doi.org/10.1038/s41573-021-00367-2openalex-snapshot
Lipogenesis inhibitors: therapeutic opportunities and challenges
inferred← citeshttps://doi.org/10.1038/s41574-019-0256-9openalex-snapshot
The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state
inferred← citeshttps://doi.org/10.1038/s41575-021-00472-yopenalex-snapshot
Dietary carbohydrates and fats in nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1038/s41586-018-0201-4openalex-snapshot
Structural basis for regulation of human acetyl-CoA carboxylase
inferred← citeshttps://doi.org/10.1038/s41591-021-01489-1openalex-snapshot
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
inferred← citeshttps://doi.org/10.1038/s41598-020-72022-6openalex-snapshot
Maternal exercise conveys protection against NAFLD in the offspring via hepatic metabolic programming
inferred← citeshttps://doi.org/10.1038/s41598-021-82208-1openalex-snapshot
High-fructose feeding does not induce steatosis or non-alcoholic fatty liver disease in pigs
inferred← citeshttps://doi.org/10.1038/s42255-020-00272-9openalex-snapshot
De novo lipogenesis is essential for platelet production in humans
inferred← citeshttps://doi.org/10.1038/s44324-024-00020-7openalex-snapshot
Some paradoxes and unresolved aspects of hepatic de novo lipogenesis
inferred← citeshttps://doi.org/10.1053/j.gastro.2018.07.027openalex-snapshot
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1055/s-0041-1731709openalex-snapshot
Role of Lipogenesis Rewiring in Hepatocellular Carcinoma.
inferred← citeshttps://doi.org/10.1080/00498254.2022.2062487openalex-snapshot
Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans
inferred← citeshttps://doi.org/10.1080/13543784.2019.1657825openalex-snapshot
Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors
inferred← citeshttps://doi.org/10.1080/13543784.2020.1668374openalex-snapshot
GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)
inferred← citeshttps://doi.org/10.1080/13543784.2020.1703949openalex-snapshot
The molecular basis for current targets of NASH therapies
inferred← citeshttps://doi.org/10.1080/14728222.2020.1728742openalex-snapshot
Emerging therapeutic targets for NASH: key innovations at the preclinical level
inferred← citeshttps://doi.org/10.1080/17474124.2018.1530110openalex-snapshot
An update on the recent advances in antifibrotic therapy
inferred← citeshttps://doi.org/10.1097/crd.0000000000000537openalex-snapshot
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association
inferred← citeshttps://doi.org/10.1097/mco.0000000000000469openalex-snapshot
Dietary carbohydrates and fatty liver disease
inferred← citeshttps://doi.org/10.1097/md.0000000000032357openalex-snapshot
Efficacy and safety of acetyl-CoA carboxylase (ACC) inhibitors in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review
inferred← citeshttps://doi.org/10.1097/mol.0000000000000720openalex-snapshot
Liver fat storage pathways: methodologies and dietary effects
inferred← citeshttps://doi.org/10.1097/xce.0000000000000197openalex-snapshot
Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists
inferred← citeshttps://doi.org/10.1111/1751-2980.12967openalex-snapshot
Efficacy and safety of drugs for nonalcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1111/dom.14272openalex-snapshot
Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials
inferred← citeshttps://doi.org/10.1111/hepr.12511openalex-snapshot
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
inferred← citeshttps://doi.org/10.1111/hepr.13688openalex-snapshot
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
inferred← citeshttps://doi.org/10.1111/liv.13972openalex-snapshot
Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1124/jpet.117.241091openalex-snapshot
Enhancing Studies of Pharmacodynamic Mechanisms via Measurements of Metabolic Flux: Fundamental Concepts and Guiding Principles for Using Stable Isotope Tracers
inferred← citeshttps://doi.org/10.1126/scitranslmed.aau8465openalex-snapshot
Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition
inferred← citeshttps://doi.org/10.1126/scitranslmed.abg8116openalex-snapshot
A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques
inferred← citeshttps://doi.org/10.1136/gutjnl-2020-320646openalex-snapshot
LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover
inferred← citeshttps://doi.org/10.1146/annurev-pathol-020117-043617openalex-snapshot
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1146/annurev-pharmtox-010617-052545openalex-snapshot
Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies
inferred← citeshttps://doi.org/10.1146/annurev-pharmtox-010716-104727openalex-snapshot
Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes
inferred← citeshttps://doi.org/10.1152/ajpendo.00470.2017openalex-snapshot
Dose-dependent quantitative effects of acute fructose administration on hepatic de novo lipogenesis in healthy humans
inferred← citeshttps://doi.org/10.11569/wcjd.v30.i16.735openalex-snapshot
Progress in research of lipogenesis inhibitors for treatment of nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1159/000493259openalex-snapshot
Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research
inferred← citeshttps://doi.org/10.1172/jci.insight.164694openalex-snapshot
Inflammation-induced TRIM21 represses hepatic steatosis by promoting the ubiquitination of lipogenic regulators
inferred← citeshttps://doi.org/10.1172/jci171267openalex-snapshot
Blood-derived lysophospholipid sustains hepatic phospholipids and fat storage necessary for hepatoprotection in overnutrition
inferred← citeshttps://doi.org/10.1194/jlr.m080101openalex-snapshot
Acetyl-CoA carboxylase 1 regulates endothelial cell migration by shifting the phospholipid composition
inferred← citeshttps://doi.org/10.1210/clinem/dgae264openalex-snapshot
LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular Diseases
inferred← citeshttps://doi.org/10.1360/ssv-2024-0098openalex-snapshot
Nonalcoholic fatty liver disease is a risk factor for cardiovascular disease
inferred← citeshttps://doi.org/10.14218/jcth.2024.00123openalex-snapshot
Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.17925/ee.2022.18.2.148openalex-snapshot
Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
inferred← citeshttps://doi.org/10.21037/tgh.2019.06.06openalex-snapshot
Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis
inferred← citeshttps://doi.org/10.2174/0929867326666190410121716openalex-snapshot
Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.2174/1570163820666230901144003openalex-snapshot
QSAR Studies and Scaffold Optimization of Predicted Novel ACC 2 Inhibitors to Treat Metabolic Syndrome
inferred← citeshttps://doi.org/10.2741/4892openalex-snapshot
Current treatment paradigms and emerging therapies for NAFLD/NASH
inferred← citeshttps://doi.org/10.31390/gradschool_dissertations.4888openalex-snapshot
Improving Coupled Enzyme Assays With Capillary Electrophoresis
inferred← citeshttps://doi.org/10.32469/10355/81575openalex-snapshot
Contribution of de novo lipogenesis to the progression of nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.32469/10355/93980openalex-snapshot
Lifestyle treatment in the regression of NASH: insulin resistance, lipid synthesis, and methodological innovation
inferred← citeshttps://doi.org/10.3389/fcell.2021.618492openalex-snapshot
Biallelic Mutations in ACACA Cause a Disruption in Lipid Homeostasis That Is Associated With Global Developmental Delay, Microcephaly, and Dysmorphic Facial Features
inferred← citeshttps://doi.org/10.3389/fmed.2021.761538openalex-snapshot
Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
inferred← citeshttps://doi.org/10.3390/antiox11030472openalex-snapshot
Lingonberry Improves Hepatic Lipid Metabolism by Targeting Notch1 Signaling
inferred← citeshttps://doi.org/10.3390/biomedicines13020393openalex-snapshot
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
inferred← citeshttps://doi.org/10.3390/cancers13143473openalex-snapshot
Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention
inferred← citeshttps://doi.org/10.3390/cells10071822openalex-snapshot
A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies
inferred← citeshttps://doi.org/10.3390/cells8101279openalex-snapshot
Magnetic-Assisted Treatment of Liver Fibrosis
inferred← citeshttps://doi.org/10.3390/ijerph16224334openalex-snapshot
Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives
inferred← citeshttps://doi.org/10.3390/ijms23094822openalex-snapshot
Liver Steatosis: A Marker of Metabolic Risk in Children
inferred← citeshttps://doi.org/10.3390/ijms26073448openalex-snapshot
Hidden in the Fat: Unpacking the Metabolic Tango Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome
inferred← citeshttps://doi.org/10.3390/ijms26094077openalex-snapshot
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
inferred← citeshttps://doi.org/10.3390/jpm12071166openalex-snapshot
Combination Therapies for Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.3390/livers3040045openalex-snapshot
Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.3390/metabo12040350openalex-snapshot
Reprogramming of Fatty Acid Metabolism in Gynaecological Cancers: Is There a Role for Oestradiol?
inferred← citeshttps://doi.org/10.3390/metabo14010012openalex-snapshot
Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
inferred← citeshttps://doi.org/10.3390/nu10121962openalex-snapshot
Myricetin Exerts Anti-Obesity Effects through Upregulation of SIRT3 in Adipose Tissue
inferred← citeshttps://doi.org/10.3390/nu13061740openalex-snapshot
High Fat Activates O-GlcNAcylation and Affects AMPK/ACC Pathway to Regulate Lipid Metabolism
inferred← citeshttps://doi.org/10.3748/wjg.v23.i36.6549openalex-snapshot
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
inferred← citeshttps://doi.org/10.3748/wjg.v27.i39.6522openalex-snapshot
Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
inferred← citeshttps://doi.org/10.5497/wjp.v9.i1.1openalex-snapshot
Advances in the treatment of nonalcoholic steatohepatitis
inferred← citeshttps://doi.org/10.5772/intechopen.100998openalex-snapshot
Non-alcoholic Fatty Liver Disease - New Insight and Glance Into Disease Pathogenesis
inferred← citeshttps://doi.org/10.5772/intechopen.106445openalex-snapshot
Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment
inferred← citeshttps://doi.org/10.5772/intechopen.107487openalex-snapshot
Therapeutic Approach to NAFLD-NASH
inferred← citeshttps://doi.org/10.5772/intechopen.108168openalex-snapshot
Hepatic Lipid Homeostasis in NAFLD
inferred← citeshttps://doi.org/10.7150/thno.36505openalex-snapshot
Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.